Bradley Theodore Hyman, M.D., Ph.D.
This page shows the publications co-authored by Bradley Hyman and Daniel Irimia.
Tau reduction in the presence of amyloid-ß prevents tau pathology and neuronal death in vivo. Brain. 2018 07 01; 141(7):2194-2212.
Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun. 2015 Oct 13; 6:8490.
Microfluidic chemotaxis platform for differentiating the roles of soluble and bound amyloid-ß on microglial accumulation. Sci Rep. 2013; 3:1823.
Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem. 2009 Oct; 111(2):417-27.
A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid ß in the brain in a transgenic model of Alzheimer disease. J Biol Chem. 2015 Jan 23; 290(4):1966-78.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.